Fluticasone propionate is a type of medication called a corticosteroid – it acts on the later phase inflammatory reaction to reduce inflammation.
Azelastine is a type of medicine called an antihistamine – it acts on the immediate phase reaction to reduce itch, sneezing and running of the nose, as well as alleviate eye symptoms.
Having the two drugs in a nasal spray means they are delivered to the area where they need to start to work giving greater symptom relief.
Having two components means Dymista® acts quickly due to the antihistamine, and has long lasting effects due to the steroid acting on the later inflammatory reaction.
Delivering the drugs to the nose means they get to work on the symptoms of allergic rhinitis as soon as possible and will alleviate nasal and eye symptoms Dymista is suitable for long term use and can be used all year round.
Dymista® Patient Information Leaflet (PIL)
The PIL contains information about your Dymista® and how to store, prepare and administer you allergic rhinitis treatment at home.
If you get any side effects or have a device failure, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. Please report side effects or device failures with any medicine or vaccine to the medicines regulator MHRA through the Yellow Card Scheme.
It is easiest and quickest to report side effects and device failures online via the Yellow Card website: https://yellowcard.mhra.gov.uk/ or search for MHRA Yellow Card in the Google Play or Apple App Store.
Alternatively, prepaid Yellow Cards for reporting are available by writing to FREEPOST YELLOW CARD (no other address details necessary), by emailing firstname.lastname@example.org, by telephoning the Commission on Human Medicines (CHM) free phone line: 0800-731-6789, or by downloading and printing a form from the Yellow Card section of the MHRA website. You can also report side effects and device failures direct to the marketing authorisation holder at email@example.com.
This website is owned and managed by Viatris. This site is intended for UK patients who have been prescribed Dymista®. We recommend that you read the full patient information leaflet carefully before using Dymista®. If you’re a Healthcare Professional, please click here.